z-logo
Premium
Microarray profile of micro‐ribonucleic acid in tumor tissue from cervical squamous cell carcinoma without human papillomavirus
Author(s) -
Zhang YanLiang,
Dai Yong,
Huang YuanShuai,
Ma Liguo,
Yin Yibing,
Tang Min,
Hu Chengxiao
Publication year - 2009
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/j.1447-0756.2009.01055.x
Subject(s) - pathogenesis , microrna , medicine , microarray , cancer research , cell , human papillomavirus , pathology , tissue microarray , basal cell , microarray analysis techniques , koilocyte , cervical cancer , western blot , gene expression , immunohistochemistry , gene , biology , cancer , genetics , cervical intraepithelial neoplasia
Aims:  Micro‐ribonucleic acid (miRNA) are noncoding RNA molecules of 21 to 24 nt that regulate the expression of target genes in a post‐transcriptional manner. Evidence indicates that miRNA play essential roles in embryogenesis, cell differentiation and pathogenesis of human diseases. This study describes a comparison between the microRNA profile of human‐papillomavirus‐negative cervical squamous cell carcinoma patients and controls, in order to develop further understanding of the pathogenesis of cervical squamous cell carcinomas. Methods:  MiRNA were isolated from tumor tissues of five human‐papillomavirus‐negative cervical squamous cell carcinoma patients and five healthy controls in order to perform miRNA microarray chip analysis. The chip results were then confirmed by northern blot analysis. Results:  A total of 27 miRNA differentially expressed between the squamous cell carcinoma patients and the healthy controls were identified. Conclusion:  This work indicates that these miRNA may be potential diagnosis biomarkers and probable factors involved in the pathogenesis of cervical squamous cell carcinomas.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here